Physician profile
Anna K Baker
NPI 1316508617
$26,289.00
in general payments reported to CMS, 2019-2025
40 companies · $6,768 in 2025
The $6,768 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,539 · 2022: $2,749 · 2023: $9,699 · 2024: $4,535 · 2025: $6,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $8,510 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Travel and Lodging: $170 · Education: $49.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,071.54 |
| Consulting Fee | $8,510.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Travel and Lodging | $170.24 |
| Education | $49.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,771.87 | 2021-2025 | |
| Emd Serono, INC. | $4,892.93 | 2021-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $2,553.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $2,056.60 | 2021-2025 | |
| Biogen, INC. | $1,721.90 | 2021-2025 | Vumerity, Tysabri, Tecfidera |
| Janssen Biotech, INC. | $1,374.85 | 2025 | |
| Alexion Pharmaceuticals, INC. | $1,163.28 | 2021-2025 | Ultomiris, Soliris |
| Abbvie INC. | $965.95 | 2021-2025 | |
| Celgene Corporation | $964.52 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $608.16 | 2021-2024 | Ajovy, Austedo, Austedo Xr |
| Genentech USA, INC. | $581.89 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $550.59 | 2021 | |
| Argenx US, INC. | $307.79 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $272.91 | 2023-2025 | Emgality, Reyvow, Kisunla |
| Ucb, INC. | $272.86 | 2023-2025 | Zilbrysq, Rystiggo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $259.77 | 2021-2025 | Uplizna |
| Pfizer INC. | $258.53 | 2023-2025 | |
| Acorda Therapeutics, INC | $190.37 | 2022-2024 | Ampyra, Inbrija |
| Horizon Therapeutics Plc | $179.96 | 2021-2023 | Uplizna |
| Lundbeck LLC | $166.47 | 2022-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $158.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $128.20 | 2021-2023 | Zeposia |
| Vanda Pharmaceuticals INC. | $127.87 | 2024-2025 | Ponvory |
| Merz Pharmaceuticals, LLC | $86.72 | 2023-2025 | Xeomin, Ampyra |
| Janssen Pharmaceuticals, INC | $86.21 | 2022 | |
| Allergan, INC. | $76.06 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.04 | 2021 | |
| Kyowa Kirin, INC. | $56.53 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $53.54 | 2023 | Nuedexta |
| Neurocrine Biosciences, INC. | $53.16 | 2022-2023 | Ingrezza, Ongentys |
| Catalyst Pharmaceuticals, INC. | $51.20 | 2022 | |
| Eisai INC. | $45.79 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.69 | 2023-2025 | Hyqvia, Gammagard |
| Mallinckrodt Hospital Products INC. | $27.89 | 2025 | Acthar |
| Alnylam Pharmaceuticals INC. | $26.62 | 2022 | |
| Ani Pharmaceuticals, INC. | $23.57 | 2023 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $20.53 | 2024 | Panzyga |
| Neurelis, INC. | $20.27 | 2022 | |
| Axsome Therapeutics, INC. | $16.16 | 2025 | Symbravo |
| Ge Healthcare | $15.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.